Howard J. Meyerson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Howard J. Meyerson has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Dale E. Huffman
Department of Physiology & Biophysics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States
3 shared publications - Fraser John Moss
Case Western Reserve University School of Medicine
3 shared publications - Pan Zhao
Department of Physiology & Biophysics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States
3 shared publications - Rossana Occhipinti
Department of Physiology & Biophysics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States
3 shared publications - Walter F. Boron
Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH 44106, USA
3 shared publications - Ahlam Salameh
VA Northeast Ohio Healthcare System (VANEOHS), Cleveland, OH, 44106, USA; Case Western Reserve University School of Medicine, Department of Neurology, Cleveland, OH, 44106, USA; Case Western Reserve University, Department of Biomedical Engineering, Cleveland, OH, 44106, USA; Kent State University College of Podiatric Medicine, Division of Preclinical Sciences, Kent, OH, 44131, USA
2 shared publications
Latest Publications
- Open Access
Role of channels in the O 2 permeability of murine red blood cells I. Stopped-flow and hematological studies
Many have believed that oxygen (O 2 ) crosses red blood cell (RBC) membranes by dissolving in lipids that offer a finite resistance to diffusion or, alternatively, no resistance at all. In this first in a series of three interrelated papers, we examine these idea in murine RBCs. In this first paper, analyses of hemoglobin (Hb) absorbance spectra during O 2 off-loading from mouse RBCs indicate that RBC membranes do indeed offer resistance to O 2 diffusion, and that the resistance would be far higher if not for the presence of O 2 -permeable channels. Two agents— both excluded from the RBC interior—markedly reduce the rate constant for O 2 off-loading ( k HbO 2 ): p-chloromercuribenzenesulfonate (pCMBS) reduces membrane O 2 permeability ( P M,O 2 by ∼82% (computed from k HbO 2 in paper #3), and 4,4’-diisothiocyanatostilbene-2,2’-disulfonate (DIDS) by ∼56%. Because neither likely produces these effects via membrane lipids, we examined RBCs from mice genetically deficient in aquaporin-1 (AQP1), the Rh complex (Rh Cx = Rhesus blood group-associated A glycoprotein, RhAG + Rhesus blood group D antigen, RhD), or both. The double knockout (dKO) reduces P M,O 2 by ∼55%, and pCMBS+dKO, by ∼91%. Proteomic analyses of RBC membranes, flow cytometry, hematology (see paper #2), and mathematical simulations (paper #3) rule out meaningful contributions from other membrane proteins, RBC geometry, or extracellular unconvected fluid (EUF). Our work represents a paradigm shift for O 2 physiology by identifying the first two animal O 2 channels, and points to the existence of at least a third, all of which could be subject to physiological regulation and pharmacological intervention. Key Points: Some have held that red-blood-cell (RBC) membranes have a finite O 2 permeability, governed by O 2 solubility in membrane lipids; others, that membranes offer no resistance whatsoever to O 2 diffusion. The present interdisciplinary study comprises three papers. This first paper describes stopped-flow absorbance spectroscopy in which we examine the rate constant of O 2 offloading from intact RBCs ( k HbO 2 ) from wild-type (WT) mice or those lacking AQP1 and/or RhAG, sometimes treated with p-chloromercuribenzenesulfonate (pCMBS) or 4,4’-diisothiocyanatostilbene-2,2’-disulfonate (DIDS). The second paper describes RBC morphometry and membrane proteomics. The third introduces a mathematical reaction-diffusion model that generates simulations comporting with physiological data. This first paper shows that pCMBS or DIDS treatments, or deletion of AQP1 and/or RhAG, or combinations thereof, substantially reduce k HbO 2 . The three papers show that WT RBC membranes offer considerable resistance to O 2 diffusion. AQP1 (∼22%), Rh (∼36%), and an unknown pCMBS-sensitive protein account for ∼91% of membrane O 2 permeability.
Open AccessRole of channels in the O 2 permeability of murine red blood cells I. Stopped-flow and hematological studies
Many have believed that oxygen (O 2 ) crosses red blood cell (RBC) membranes by dissolving in lipids that offer a finite resistance to diffusion or, alternatively, no resistance at all. In this first in a series of three interrelated papers, we examine these idea in murine RBCs. In this first paper, analyses of hemoglobin (Hb) absorbance spectra during O 2 off-loading from mouse RBCs indicate that RBC membranes do indeed offer resistance to O 2 diffusion, and that the resistance would be far higher if not for the presence of O 2 -permeable channels. Two agents— both excluded from the RBC interior—markedly reduce the rate constant for O 2 off-loading ( k HbO 2 ): p-chloromercuribenzenesulfonate (pCMBS) reduces membrane O 2 permeability ( P M,O 2 by ∼82% (computed from k HbO 2 in paper #3), and 4,4’-diisothiocyanatostilbene-2,2’-disulfonate (DIDS) by ∼56%. Because neither likely produces these effects via membrane lipids, we examined RBCs from mice genetically deficient in aquaporin-1 (AQP1), the Rh complex (Rh Cx = Rhesus blood group-associated A glycoprotein, RhAG + Rhesus blood group D antigen, RhD), or both. The double knockout (dKO) reduces P M,O 2 by ∼55%, and pCMBS+dKO, by ∼91%. Proteomic analyses of RBC membranes, flow cytometry, hematology (see paper #2), and mathematical simulations (paper #3) rule out meaningful contributions from other membrane proteins, RBC geometry, or extracellular unconvected fluid (EUF). Our work represents a paradigm shift for O 2 physiology by identifying the first two animal O 2 channels, and points to the existence of at least a third, all of which could be subject to physiological regulation and pharmacological intervention. Key Points: Some have held that red-blood-cell (RBC) membranes have a finite O 2 permeability, governed by O 2 solubility in membrane lipids; others, that membranes offer no resistance whatsoever to O 2 diffusion. The present interdisciplinary study comprises three papers. This first paper describes stopped-flow absorbance spectroscopy in which we examine the rate constant of O 2 offloading from intact RBCs ( k HbO 2 ) from wild-type (WT) mice or those lacking AQP1 and/or RhAG, sometimes treated with p-chloromercuribenzenesulfonate (pCMBS) or 4,4’-diisothiocyanatostilbene-2,2’-disulfonate (DIDS). The second paper describes RBC morphometry and membrane proteomics. The third introduces a mathematical reaction-diffusion model that generates simulations comporting with physiological data. This first paper shows that pCMBS or DIDS treatments, or deletion of AQP1 and/or RhAG, or combinations thereof, substantially reduce k HbO 2 . The three papers show that WT RBC membranes offer considerable resistance to O 2 diffusion. AQP1 (∼22%), Rh (∼36%), and an unknown pCMBS-sensitive protein account for ∼91% of membrane O 2 permeability.
- Open Access
Role of channels in the O 2 permeability of murine red blood cells II. Morphological and proteomic studies
In this second of three papers, we examine red blood cell (RBC) morphometry and RBC-membrane proteomics from our laboratory mouse strain (C57BL/6 Case ). In paper #1 , using stopped-flow absorbance spectroscopy to ascertain the rate constant for oxyhemoglobin (HbO 2 ) deoxygenation ( k HbO 2 ), we find substantial k HbO 2 reductions with (1) membrane-protein inhibitors p-chloromercuribenzenesulfonate (pCMBS) or 4,4’-diisothiocyanatostilbene-2,2’-disulfonate (DIDS); (2) knockouts of aquaporin-1 (AQP1-KO), or Rhesus blood-group–associated A-glycoprotein (RhAG-KO), or double knockouts (dKO); or (3) inhibitor+dKO. In paper #3 , reaction-diffusion mathematical modeling/simulations reveal that k HbO 2 could fall secondary to slowed intracellular O 2 /HbO 2 /Hb diffusion. Here in paper #2 , blood smears as well as still/video images and imaging flow cytometry (IFC) of living RBCs show that ∼97.5% to ∼98.6% of control (not drug-treated) cells are biconcave disks (BCDs) across all genotypes. Pretreatment with pCMBS raises non-BCD abundance to ∼8.7% for WT and ∼5.7% for dKO; for DIDS pretreatment, the figures are ∼41% and ∼21%, respectively. Modeling ( paper #3 ) accommodates for these shape changes. Light-scattering flow cytometry shows no significant difference in RBC size or shape among genotypes. IFC reveals minor differences among genotypes in RBC major diameter (Ø Major ), which (along with mean corpuscular volume, paper #1 ) yields RBC thickness for simulations in paper #3. Label-free liquid chromatography/tandem mass spectrometry (LC/MS/MS) proteomic analyses of RBC plasma-membrane ghosts confirm the deletion of proteins targeted by our knockouts, and rule out changes in the 100 proteins of greatest inferred abundance. Thus, genetically induced changes in k HbO 2 must reflect altered abundance of AQP1 and /or the Rh complex. Key Points: O 2 -offloading from red blood cells (RBCs) depends not only on membrane O 2 permeability and oxyhemoglobin dissociation, but also on RBC size and shape. In this second of three papers, we use blood smears, still/video images of living RBCs, and imaging flow cytometry to examine morphometry of RBCs from paper #1 . We find that mouse RBCs of all genotypes—wild-type, aquaporin-1 knockout (AQP1-KO), Rhesus blood group-associated A-glycoprotein knockout (RhAG-KO), and double knockout—are dominantly biconcave discs, with ∼1.4% to ∼2.5% poikilocytosis (shape change, SC). Drug pre-treatment increases %SC. Using label-free liquid chromatography/tandem mass spectrometry to assess apparent abundance of RBC-ghost proteins, we find no significant differences among genotypes for any of the ∼100 most abundant protein species except, as appropriate, AQP1, RhAG, or Rhesus blood group D antigen. Thus, the substantial effects observed in paper #1 cannot be attributed to differences in morphometry or protein content.
Open AccessRole of channels in the O 2 permeability of murine red blood cells II. Morphological and proteomic studies
In this second of three papers, we examine red blood cell (RBC) morphometry and RBC-membrane proteomics from our laboratory mouse strain (C57BL/6 Case ). In paper #1 , using stopped-flow absorbance spectroscopy to ascertain the rate constant for oxyhemoglobin (HbO 2 ) deoxygenation ( k HbO 2 ), we find substantial k HbO 2 reductions with (1) membrane-protein inhibitors p-chloromercuribenzenesulfonate (pCMBS) or 4,4’-diisothiocyanatostilbene-2,2’-disulfonate (DIDS); (2) knockouts of aquaporin-1 (AQP1-KO), or Rhesus blood-group–associated A-glycoprotein (RhAG-KO), or double knockouts (dKO); or (3) inhibitor+dKO. In paper #3 , reaction-diffusion mathematical modeling/simulations reveal that k HbO 2 could fall secondary to slowed intracellular O 2 /HbO 2 /Hb diffusion. Here in paper #2 , blood smears as well as still/video images and imaging flow cytometry (IFC) of living RBCs show that ∼97.5% to ∼98.6% of control (not drug-treated) cells are biconcave disks (BCDs) across all genotypes. Pretreatment with pCMBS raises non-BCD abundance to ∼8.7% for WT and ∼5.7% for dKO; for DIDS pretreatment, the figures are ∼41% and ∼21%, respectively. Modeling ( paper #3 ) accommodates for these shape changes. Light-scattering flow cytometry shows no significant difference in RBC size or shape among genotypes. IFC reveals minor differences among genotypes in RBC major diameter (Ø Major ), which (along with mean corpuscular volume, paper #1 ) yields RBC thickness for simulations in paper #3. Label-free liquid chromatography/tandem mass spectrometry (LC/MS/MS) proteomic analyses of RBC plasma-membrane ghosts confirm the deletion of proteins targeted by our knockouts, and rule out changes in the 100 proteins of greatest inferred abundance. Thus, genetically induced changes in k HbO 2 must reflect altered abundance of AQP1 and /or the Rh complex. Key Points: O 2 -offloading from red blood cells (RBCs) depends not only on membrane O 2 permeability and oxyhemoglobin dissociation, but also on RBC size and shape. In this second of three papers, we use blood smears, still/video images of living RBCs, and imaging flow cytometry to examine morphometry of RBCs from paper #1 . We find that mouse RBCs of all genotypes—wild-type, aquaporin-1 knockout (AQP1-KO), Rhesus blood group-associated A-glycoprotein knockout (RhAG-KO), and double knockout—are dominantly biconcave discs, with ∼1.4% to ∼2.5% poikilocytosis (shape change, SC). Drug pre-treatment increases %SC. Using label-free liquid chromatography/tandem mass spectrometry to assess apparent abundance of RBC-ghost proteins, we find no significant differences among genotypes for any of the ∼100 most abundant protein species except, as appropriate, AQP1, RhAG, or Rhesus blood group D antigen. Thus, the substantial effects observed in paper #1 cannot be attributed to differences in morphometry or protein content.
- 1 January 2022
- Published by Elsevier in Leukemia Research
- Vol. 112, 106752
Decreased CD177pos neutrophils in myeloid neoplasms is associated with NPM1, RUNX1, TET2, and U2AF1 S34F mutations
- 1 January 2022
- Published by Elsevier in Leukemia Research
- Vol. 112, 106752
Decreased CD177pos neutrophils in myeloid neoplasms is associated with NPM1, RUNX1, TET2, and U2AF1 S34F mutations
- 1 January 2021
- Published by Wiley in European Journal of Haematology
- Vol. 106 (4) , 500-507
Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS‐type molecular findings compared to CCUS without dysplasia
Objectives: Although morphologic dysplasia is not typically considered a feature of CCUS, we have consistently observed low‐level bone marrow (BM) dysplasia among CCUS patients. We sought to determine whether sub‐diagnostic BM dysplasia in CCUS patients is associated with other clinico‐pathologic findings of myelodysplastic syndrome (MDS).Methods: We identified 49 CCUS patients, 25 with sub‐diagnostic dysplasia (CCUS‐D), and 24 having no dysplasia (CCUS‐ND). We compared the clinical, histologic, and laboratory findings of CCUS‐D and CCUS‐ND patients to 49 MDS patients, including blood cell counts, BM morphology, flow cytometry, cytogenetics, and results of next‐generation sequencing.Results: No statistically significant differences were observed between CCUS‐D and CCUS‐ND patients in the degree of cytopenias, BM cellularity, myeloid‐to‐erythroid ratio, or the presence of flow cytometric abnormalities. However, compared to CCUS‐ND, CCUS‐D patients exhibited increased mutations in myeloid malignancy‐associated genes, including non‐TET2/DNMT3A/ASXL1 variants, spliceosome (SF3B1, SRSF2, ZRSR2, or U2AF1) variants, and IDH2/RUNX1/CBL variants. CCUS‐D patients were also enriched for higher variant allele frequencies and co‐mutation of TET2/DNMT3A/ASXL1 with other genes.Conclusions: CCUS‐D patients exhibit a molecular (but not clinical) profile more similar to MDS patients than CCUS‐ND, suggesting CCUS‐D may represent a more immediate precursor to MDS and may warrant closer clinical follow‐up.
- 1 January 2021
- Published by Wiley in European Journal of Haematology
- Vol. 106 (4) , 500-507
Clonal cytopenia of undetermined significance (CCUS) with dysplasia is enriched for MDS‐type molecular findings compared to CCUS without dysplasia
Objectives: Although morphologic dysplasia is not typically considered a feature of CCUS, we have consistently observed low‐level bone marrow (BM) dysplasia among CCUS patients. We sought to determine whether sub‐diagnostic BM dysplasia in CCUS patients is associated with other clinico‐pathologic findings of myelodysplastic syndrome (MDS).Methods: We identified 49 CCUS patients, 25 with sub‐diagnostic dysplasia (CCUS‐D), and 24 having no dysplasia (CCUS‐ND). We compared the clinical, histologic, and laboratory findings of CCUS‐D and CCUS‐ND patients to 49 MDS patients, including blood cell counts, BM morphology, flow cytometry, cytogenetics, and results of next‐generation sequencing.Results: No statistically significant differences were observed between CCUS‐D and CCUS‐ND patients in the degree of cytopenias, BM cellularity, myeloid‐to‐erythroid ratio, or the presence of flow cytometric abnormalities. However, compared to CCUS‐ND, CCUS‐D patients exhibited increased mutations in myeloid malignancy‐associated genes, including non‐TET2/DNMT3A/ASXL1 variants, spliceosome (SF3B1, SRSF2, ZRSR2, or U2AF1) variants, and IDH2/RUNX1/CBL variants. CCUS‐D patients were also enriched for higher variant allele frequencies and co‐mutation of TET2/DNMT3A/ASXL1 with other genes.Conclusions: CCUS‐D patients exhibit a molecular (but not clinical) profile more similar to MDS patients than CCUS‐ND, suggesting CCUS‐D may represent a more immediate precursor to MDS and may warrant closer clinical follow‐up.
- Open Access
Role of channels in the oxygen permeability of red blood cells
Many have believed that oxygen (O 2 ) crosses red blood cell (RBC) membranes by dissolving in lipids that offer no resistance to diffusion. However, using stopped-flow (SF) analyses of hemoglobin (Hb) absorbance spectra during O 2 off-loading from mouse RBCs, we now report that most O 2 traverses membrane-protein channels. Two agents excluded from the RBC interior markedly slow O 2 off-loading: p-chloromercuribenzenesulfonate (pCMBS) reduces inferred membrane O 2 permeability ( P Membrane ) by ∼82%, and 4,4’-diisothiocyanatostilbene-2,2’-disulfonate (DIDS), by ∼56%. Because neither likely produces these effects via membrane lipids, we examined RBCs from mice genetically deficient in aquaporin-1 (AQP1), the Rh complex (i.e., rhesus proteins RhAG + mRh), or both. The double knockout (dKO) reduces P Membrane by ∼55%, and pCMBS+dKO, by ∼91%. Proteomic analyses of RBC membranes, flow cytometry, hematology, and mathematical simulations rule out explanations involving other membrane proteins, RBC geometry, or extracellular unconvected fluid (EUF). By identifying the first two O 2 channels and pointing to the existence of other O 2 channel(s), all of which could be subject to physiological regulation and pharmacological intervention, our work represents a paradigm shift for O 2 handling.
Open AccessRole of channels in the oxygen permeability of red blood cells
Many have believed that oxygen (O 2 ) crosses red blood cell (RBC) membranes by dissolving in lipids that offer no resistance to diffusion. However, using stopped-flow (SF) analyses of hemoglobin (Hb) absorbance spectra during O 2 off-loading from mouse RBCs, we now report that most O 2 traverses membrane-protein channels. Two agents excluded from the RBC interior markedly slow O 2 off-loading: p-chloromercuribenzenesulfonate (pCMBS) reduces inferred membrane O 2 permeability ( P Membrane ) by ∼82%, and 4,4’-diisothiocyanatostilbene-2,2’-disulfonate (DIDS), by ∼56%. Because neither likely produces these effects via membrane lipids, we examined RBCs from mice genetically deficient in aquaporin-1 (AQP1), the Rh complex (i.e., rhesus proteins RhAG + mRh), or both. The double knockout (dKO) reduces P Membrane by ∼55%, and pCMBS+dKO, by ∼91%. Proteomic analyses of RBC membranes, flow cytometry, hematology, and mathematical simulations rule out explanations involving other membrane proteins, RBC geometry, or extracellular unconvected fluid (EUF). By identifying the first two O 2 channels and pointing to the existence of other O 2 channel(s), all of which could be subject to physiological regulation and pharmacological intervention, our work represents a paradigm shift for O 2 handling.
- Open Access
- 29 July 2020
- Published by Wiley in British Journal of Haematology
- Vol. 191 (2) , E61-E64
Reciprocal ATP5L–KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B‐ALL) patient
- 29 July 2020
- Published by Wiley in British Journal of Haematology
- Vol. 191 (2) , E61-E64
Open AccessReciprocal ATP5L–KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B‐ALL) patient
- 1 February 2019
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 19 (2) , 73-82
Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia
- 1 February 2019
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 19 (2) , 73-82
Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia
- 1 October 2017
- Published by Elsevier in Human Pathology
- Vol. 68, 147-153
Juvenile myelomonocytic leukemia with prominent CD141+ myeloid dendritic cell differentiation
- 1 October 2017
- Published by Elsevier in Human Pathology
- Vol. 68, 147-153
Juvenile myelomonocytic leukemia with prominent CD141+ myeloid dendritic cell differentiation
- 1 February 2015
- Vol. 8 (2) , 1613-21
CD317 is over-expressed in B-cell chronic lymphocytic leukemia, but not B-cell acute lymphoblastic leukemia.
CD317 was first identified as a multiple myeloma-associated antigen. Here we report the expression of CD317 in normal B cells and B-cell malignancies. In normal bone marrow, CD317 demonstrates a biphasic expression pattern, with higher expression on stage 1 and stage 3 hematogones, but not on stage 2 hematogones. CD317 is over-expressed in B-cell chronic lymphocytic leukemia, and appears associated with negative CD38 expression. Moreover, CD317 is barely detectable in B-cell acute lymphoblastic leukemia. Our results suggest that CD317 expression might be of prognostic significance for B-CLL, and CD317 could be used as a new marker for minimal residual disease detection in B-ALL.
- 1 February 2015
- Vol. 8 (2) , 1613-21
CD317 is over-expressed in B-cell chronic lymphocytic leukemia, but not B-cell acute lymphoblastic leukemia.
CD317 was first identified as a multiple myeloma-associated antigen. Here we report the expression of CD317 in normal B cells and B-cell malignancies. In normal bone marrow, CD317 demonstrates a biphasic expression pattern, with higher expression on stage 1 and stage 3 hematogones, but not on stage 2 hematogones. CD317 is over-expressed in B-cell chronic lymphocytic leukemia, and appears associated with negative CD38 expression. Moreover, CD317 is barely detectable in B-cell acute lymphoblastic leukemia. Our results suggest that CD317 expression might be of prognostic significance for B-CLL, and CD317 could be used as a new marker for minimal residual disease detection in B-ALL.
- Open Access
- 1 March 2007
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 131 (3) , 468-472
Measuring the Clinical Impact of Pathologist Reviews of Blood and Body Fluid Smears
Context.—Despite the widespread practice of pathologist review of blood and body fluid smears, little is known about its impact on improving patient care. Objective.—To assess the clinical usefulness of pathologist review of blood and body fluid smears. Design.—Survey study. Pathology residents contacted the ordering physician after pathologist reviews were reported to assess their clinical impact. Results.—Ninety-six pathologist reviews met criteria for study inclusion, and 64 ordering physicians were successfully contacted during the 2-month study period. Of the 64 cases, 19 reviews (30%) had been seen by the physician within 24 to 48 hours after the report was issued and 33 (51%) had not been seen; in 4 (6%) instances, physicians did not remember whether they had seen the review. Eight reviews (13%) were considered urgent enough to warrant immediate communication by the pathologist. Of the 27 reviews that were seen or directly communicated, 23 (85%) contributed to clinical diagnosis and/or patient management. Conclusions.—This study demonstrates the contribution of pathologist reviews of blood and body fluids to clinical diagnosis and patient management. The results also highlight the problem of a lack of physician awareness of clinical pathology results.
- 1 March 2007
- Published by Archives of Pathology and Laboratory Medicine in Archives of Pathology & Laboratory Medicine
- Vol. 131 (3) , 468-472
Open AccessMeasuring the Clinical Impact of Pathologist Reviews of Blood and Body Fluid Smears
Context.—Despite the widespread practice of pathologist review of blood and body fluid smears, little is known about its impact on improving patient care. Objective.—To assess the clinical usefulness of pathologist review of blood and body fluid smears. Design.—Survey study. Pathology residents contacted the ordering physician after pathologist reviews were reported to assess their clinical impact. Results.—Ninety-six pathologist reviews met criteria for study inclusion, and 64 ordering physicians were successfully contacted during the 2-month study period. Of the 64 cases, 19 reviews (30%) had been seen by the physician within 24 to 48 hours after the report was issued and 33 (51%) had not been seen; in 4 (6%) instances, physicians did not remember whether they had seen the review. Eight reviews (13%) were considered urgent enough to warrant immediate communication by the pathologist. Of the 27 reviews that were seen or directly communicated, 23 (85%) contributed to clinical diagnosis and/or patient management. Conclusions.—This study demonstrates the contribution of pathologist reviews of blood and body fluids to clinical diagnosis and patient management. The results also highlight the problem of a lack of physician awareness of clinical pathology results.